<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04094285</url>
  </required_header>
  <id_info>
    <org_study_id>OPHT-070119</org_study_id>
    <nct_id>NCT04094285</nct_id>
  </id_info>
  <brief_title>The Effect of Hyperoxia and Hypoxia on Fluorescence Lifetime Imaging Ophthalmoscopy in Healthy Subjects- a Randomized, Double Blind, Crossover Study</brief_title>
  <official_title>The Effect of Hyperoxia and Hypoxia on Fluorescence Lifetime Imaging Ophthalmoscopy in Healthy Subjects- a Randomized, Double Blind, Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims to investigate whether FLIO can also detect shorttime changes in
      retinal metabolism induced by hyperoxia and hypoxia. For this purpose, 48 healthy subjects
      will be included in the present study and changes in FLIO will be assessed during breathing
      of 100% oxygen to induce hyperoxia as well as during breathing of 12% oxygen in nitrogen to
      induce hypoxia. Since stimulation with flickering light also induces a higher metabolic
      demand in the retina (functional hyperemia), thisprovocation test will also applied during
      breathing of the different gas mixtures and compared to baseline. To gain information about
      retinal blood flow, optical coherence tomography angiography (OCT-A) will be performed. The
      results of the present study can help to gain more insight into the physiology of the retinal
      metabolism and might give grounds to establish new biomarkers in future studies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2019</start_date>
  <completion_date type="Anticipated">October 2, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in FLIO induced by hyperoxia</measure>
    <time_frame>15 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in FLIO induced by hypoxia</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in FLIO induced by flicker stimulation</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in OCT-A induced by hyperoxia</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in OCT-A induced by hypoxia</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in OCT-A induced by flicker stimulation</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal oxygen saturation</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal vessel diameter</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in peripheral oxygen saturation</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood gas parameters (pH, pCO2, PO2 and SaO2)</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>To Investigate the Effect of 100% Oxygen Breathing on Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO) in Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAUERSTOFF</intervention_name>
    <description>SAUERSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria
Dose:
min. 95.5%, breathing for 30 minutes</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STICKSTOFF</intervention_name>
    <description>STICKSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria
Dose:
88% with 12% oxygen, breathing for 30 minutes</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged between 18 and 35 years

               -  Normal ophthalmic findings

               -  Ametropia â‰¤ 6 diopters

               -  Normal findings in the medical history and physical examination including ECG
                  unless the investigator considers an abnormality to be clinically irrelevant

               -  Nonsmokers

        Exclusion Criteria:

        Regular use of medication, abuse of alcoholic beverages or drugs

          -  Participation in a clinical trial in the 3 weeks preceding the study

          -  Treatment in the previous 3 weeks with any drug (except contraceptives)

          -  Symptoms of a clinically relevant illness in the 3 weeks before the first study day

          -  Blood donation during the previous 3 weeks

          -  History or family history of epilepsy

          -  Pregnant or breast-feeding women

          -  Women of childbearing potential (neither menopausal, nor hysterectomized, nor
             sterilized) not using effective contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna, Austria</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Garhofer, MD</last_name>
      <phone>+43 1 40400</phone>
      <phone_ext>29810</phone_ext>
      <email>gerhard.garhoefer@meduniwien.ac.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 16, 2019</study_first_submitted>
  <study_first_submitted_qc>September 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2019</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Gerhard Garhofer</investigator_full_name>
    <investigator_title>Assoc. Prof. PD. Dr. med. univ.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Hyperoxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

